Citation

  • Authors: Dombernowsky, S. L., Samsoe-Petersen, J., Petersen, C. H., Instrell, R., Hedegaard, A. M., Thomas, L., Atkins, K. M., Auclair, S., Albrechtsen, R., Mygind, K. J., Frohlich, C., Howell, M., Parker, P., Thomas, G., Kveiborg, M.
  • Year: 2015
  • Journal: Nat Commun 6 7518
  • Applications: in vitro / siRNA / INTERFERin
  • Cell types:
    1. Name: HT-1080
      Description: Human acetabulum fibrosarcoma cells
      Known as: HT1080
    2. Name: HeLa
      Description: Human cervix epitheloid carcinoma cells
    3. Name: MCF7
      Description: Human breast adenocarcinoma cells
      Known as: MCF-7, MCF 7

Method

Cells were transfected with siRNAs diluted to 375nM in Opti-MEM using INTERFERin transfection reagent diluted in Opti-MEM, according to the manufacturer’s instructions.

Abstract

The metalloproteinase ADAM17 activates ErbB signalling by releasing ligands from the cell surface, a key step underlying epithelial development, growth and tumour progression. However, mechanisms acutely controlling ADAM17 cell-surface availability to modulate the extent of ErbB ligand release are poorly understood. Here, through a functional genome-wide siRNA screen, we identify the sorting protein PACS-2 as a regulator of ADAM17 trafficking and ErbB signalling. PACS-2 loss reduces ADAM17 cell-surface levels and ADAM17-dependent ErbB ligand shedding, without apparent effects on related proteases. PACS-2 co-localizes with ADAM17 on early endosomes and PACS-2 knockdown decreases the recycling and stability of internalized ADAM17. Hence, PACS-2 sustains ADAM17 cell-surface activity by diverting ADAM17 away from degradative pathways. Interestingly, Pacs2-deficient mice display significantly reduced levels of phosphorylated EGFR and intestinal proliferation. We suggest that this mechanism controlling ADAM17 cell-surface availability and EGFR signalling may play a role in intestinal homeostasis, with potential implications for cancer biology.

Go to